AVYCAZ (Ceftazidime and Avibactam) Patent

This is a Hatch-Waxman patent docket brought by the branded manufacturer of AVYCAZ, an antibacterial medicine used to treat serious bacterial infections, against a generic drug company that filed an abbreviated new drug application seeking approval to market a generic version. Centralized in the District of New Jersey in 2025 to coordinate two related actions filed in different districts against the same generic manufacturer over the same product, the docket now carries 1 pending action.

As with other branded-generic pharmaceutical patent disputes, this is not a matter where plaintiff-side or defense-side litigation funding applies: both the branded manufacturer and the generic-company defendant are established pharmaceutical businesses capable of financing their own litigation without an outside capital partner, and there is no individual claimant population or damages class involved.

This docket's relevance to a capital or intelligence desk is limited to its value as a small, clean illustration of how the JPML consolidates even a two-action Hatch-Waxman dispute once the same generic manufacturer is litigating the same patents in more than one district, avoiding duplicated claim-construction and validity proceedings over identical patent claims. Criterica Capital does not treat this docket as a funding target; it is referenced only for comparative purposes when evaluating genuinely fundable claims in adjacent pharmaceutical patent matters.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.